News Phase III Study Shows Roche's Hemophilia… – Genetic Engineering & Biotechnology News
Reuters UK |
News Phase III Study Shows Roche’s Hemophilia…
Genetic Engineering & Biotechnology News Roche reported positive interim data from its second Phase III emicizumab (ACE910) trial, HAVEN 2, demonstrating that prophylactic use of the bispecific monoclonal antibody (mAb) reduced the number of bleeding episodes in children under the age of 12 … Roche’s emicizumab hemophilia drug shows positive results with children Emicizumab reduces bleeds among children with hemophilia A Roche’s emicizumab treats hemophilia A in children |
View original article
Author:
Powered by WPeMatico
Health Topic Contributor
Editors and curators bringing you the latest and most impactful health news. Truly objective, we print links to stories and studies that may contradict one another. If you're searching for news on health studies, alternative health modalities, facts on modern allopathic medicine, and more, we're you're team bringing you the stories and facts that matter.